About Us
We are passionate about the use of science and AI to push the boundaries of medical understanding and diagnostics. We aim to become a trusted provider of responsible and clinically validated AI tools to improve healthcare worldwide for early diagnosis, better disease treatment, and equal access to the best medical advice.
We are also an institutional member of the Canadian College of Healthcare Leaders and of the London Royal Society of Medicine.
Headquartered outside London in the UK but operating globally, our 50+ staff is distributed around the world. Our commercial team operates from the UK, U.S., Canada, and India. Our AI research groups are located in the UK and Abu Dhabi, UAE; our biochemical labs are located in Reading, UK, and in Atlanta, U.S.; and our software development teams are based in India (front-end) and Bangladesh (back-end). We are united in our dedication to developing a person-centric approach to healthcare that differs from the current population-based paradigm.
The team exploits its research experience carried out at top-ranked institutions at the forefront of AI and medicine, including Oxford, Cambridge, and Karolinska. OIA’s founders have published more than 200 papers in all the top-ranked journals in the areas of Artificial Intelligence, computational medicine, and systems immunology.
Our cross-disciplinary team consists of AI experts, medical leaders, and pioneers in IoT and optical engineering working at the forefront of science and technology. With our multidisciplinary approach, we are able to tackle some of the most pressing human health challenges, such as infection, cancer, antibiotic resistance, and tropical diseases from a technological and commercial-viability point of view.
Our Team
An elected member of the London Mathematical Society and member of the Canadian College of Health Leaders (CCHL), as a Senior Researcher and faculty member in the Department of Computer Science, University of Oxford, he has published over 100 papers and a dozen of books, including A Computable Universe with a foreword by Sir Roger Penrose (Nobel Prize in Physics, 2020).
In 2021, he was appointed Senior Researcher by the Alan Turing Institute at the British Library in London to advise the UK and allies on the future of Artificial Intelligence for scientific discovery, a position funded by the U.S. Department of Defense. In his capacity as policy advisor he has led discussions on the global stage, under the auspices of organisations such as the OECD.
After joining the Unit of Computational Medicine as an Assistant Professor he became the leader of the Algorithmic Dynamics Lab at the Karolinska Institute (the institution that awards the Nobel Prize in Physiology or Medicine), also affiliated with SciLifeLab and the Karolinska Hospital in Stockholm, Sweden.
He was a NASA Payload team member at MIT in Boston MA for the Mars Gravity Biosatellite to test the health effects of artificial microgravity on mammals. He helped develop the factual answering AI engine behind Siri and Alexa, reporting to Wolfram Research’s CEO, Stephen Wolfram in Champaign, IL.
He has been featured in Wired, the New York Times, Le Monde, Scientific American, New Scientist, The Independent, and the MIT Technology Review, among other media venues.
A theoretical physicist (PhD) by training, he has conducted research into black holes and dark matter, quantum gravity and boson stars, as well as cellular automata and complexity science. His expertise encompasses extensive knowledge of database systems, data migration, business intelligence, analytics, data science, data visualisation, data governance and compliance. He has worked for major corporations in the private banking, automobile, manufacturing, and energy industries, including UBS, Citibank, Volkswagen, Zalando, Munich RE, Eon and, most recently, Rabobank.
EMBA (SMU, Halifax, NS, Canada). As a Senior Healthcare Executive, Pam was formerly Director of Health Policy, Stakeholder Engagement and Chief Marketing Officer for Medtronic, Canada. Medtronic is the world’s largest medical devices company. With more than 25 years in the healthcare industry, she began her career as a Critical Care Nurse and then moved to the pharmaceutical industry, successfully supporting women’s health, neurology and oncology faculties. Pam is a visionary leader in the area of value-based healthcare strategies and is skilled in understanding how to position new solutions and technologies in today’s dynamic healthcare marketplace.
He has been a director of a number of public and private companies and is currently a director and the CEO of Range Energy Resources Inc., listed on the Canadian Securities Exchange. His background includes hedge funds, corporate oil and gas, private equity and financial services, with experience and knowledge of capital markets from both the buy and sell perspectives. He has spent time financing and advising a number of private and public entities, achieving notable success with Altus, Bluewave Energy, FCF Capital, Polaris Infrastructure.
Lead oncologist at the Department of Paediatric Haematology, Oncology and Palliative Care, NHS Cambridge University Trust. He is a childhood cancer specialist working at Addenbrooke’s Hospital, providing service to children in the East of England. He is an authority on children’s leukaemia and is responsible, as Cancer Specialist Lead, for the delivery of clinical cancer trials for children and young people in England. He is a member of the National Cancer Research Institute Lymphoma Clinical Studies Group and chairs its paediatric Non-Hodgkin Lymphoma subgroup.
Prof. Patrick Tighe is Professor of Molecular Immunology within the Faculty of Medicine and Health Sciences at the University of Nottingham. Prof. Tighe has many years of experience in molecular cloning technologies, T cell receptor analysis, transcriptomics, fluorescent detection technologies and immunoassay technologies. He has a strong interest in laboratory automation, liquid handling robotics; lab-on-a-chip technologies; high-throughput ELISA and protein microarray analysis for applications in serology and intracellular signalling pathway analysis.
He has research interests in rare autoinflammatory conditions and systemic autoimmune diseases and spent many years investigating the molecular mechanisms associated with defects in the TNFR1 receptor, which gives rise to TNF-receptor-associated periodic syndrome (TRAPS). More recently, he has developed collaborative projects for the early diagnosis of cancer (autoantibody detection) and alternatives to TMA tumour staining (tumour antigen detection).
Petter Brodin is Garfield Weston Chair and Professor of Paediatric Immunology at Imperial College London and Professor of Paediatric immunology at Karolinska Institutet in Stockholm, Sweden.
The Brodin lab (
Human Immune Variation ) develops and applies novel experimental and computational methods to describe human immune system variation, with a particular emphasis on the immune systems of children, its development early in life, and its role in health and disease during childhood.
Brodin established a national facility for immunomonitoring at the Swedish infrastructure hub, Science for Life Laboratory. He also established his own research program applying systems-immunology methods to the study of immune system development early in life. The Brodin lab established a birth cohort and showed differences in early life adaptation between preterm and term infants (Olin et al, Cell, 2018), the global repertoire of maternal antiviral antibodies (Pou et al, Nat. Med, 2019) as well as the imprinting effect of select colonising microbes such as bifidobacteria early in life (Henrick et al, Cell, 2021). During the COVID-19 pandemic, the Brodin lab also applied its technologies for systems-level immune system analysis to understanding COVID-19 in children (Brodin, P, Immunity 2022), the immunology of MIS-C (Consiglio et al, Cell, 2020) and severe COVID-19 (Rodriguez et al, Cell Reports Med, 2020). The lab is an active member of the global COVID-Human Genetic Effort.
Prof Brodin’s Affiliations:
Petter Brodin, M.D., Ph.D. Honorary consultant, Paediatric Immunology
Garfield Weston Chair and Professor of Paediatric Immunology
Department of Inflammation and Immunology
Imperial College London, London UK
Professor of Paediatric Immunology
Department of Women’s and Children’s Health
Karolinska Institutet, Stockholm, Sweden
Dr. Berman is a widely respected clinician, researcher and thought leader and serves as CEO and Scientific Director of the Children’s Hospital of Eastern Ontario (CHEO) Research Institute and as Vice President, Research at CHEO. He is also a Full Professor of Paediatrics and Cellular and Molecular Medicine at the University of Ottawa, having previously served as Professor of Pediatrics, Microbiology, Immunology and Pathology at Dalhousie University, and interim Vice President, Research, Innovation and Knowledge Translation for the IWK Health Centre in Halifax, Nova Scotia. Dr. Berman is also well known for his systems-thinking approach and pioneering research in zebrafish modelling of childhood cancer and orphan diseases. He is past- President of the Canadian Society of Clinical Investigation, President of the Canadian Haematology Society, and is a founding member of the Canadian Rare Disease Models and Mechanisms Network.
MD, MPH, FRCP(C) is the Medical Director of the Stem Cell Transplantation Program at the Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. Dr. Cutler graduated from McGill University’s Faculty of Medicine, completed a residency in Internal Medicine at the McGill University Health Science Center, and completed fellowship training in hematology, medical oncology, and stem cell transplantation at the Dana-Farber Cancer Institute. Dr. Cutler earned an MPH degree at the Harvard School of Public Health. Dr. Cutler has been a contributing author on more than 300 peer-reviewed publications and 40 reviews and book chapters. His research focuses on development of novel methods of acute and chronic graft-vs.-host disease prophylaxis and therapy, and decision theory in stem cell transplantation.
Associate Professor of Informatics and Digital Health, Deputy Director in Informatics Research Centre, Henley Business School, University of Reading. Principal Investogator of the EPSRC project on the ‘Future blood testing for inclusive monitoring and personalised analytics Network+’, her research focuses on digital health, integrated systems, AI, and machine learning applications in healthcare. She has been a scientific advisor for the company responsible for a mobile healthcare and data platform used in 3000 hospitals in China. Her research impact for improving healthcare quality and efficiency using data and AI was recognised as one of the winners of O2RB Excellence in Impact Awards in 2018, supported by the University of Oxford Economic Social Research Council Impact Acceleration Account.
Tony Cambridge is the Managing Director of Thornhill Healthcare Events and Consultancy and Lead Biomedical Scientist in the Pathology Management team of a major trauma centre and acute care NHS hospital in England. With over 25 years’ experience in pathology and diagnostics he frequently consults for companies in the diagnostic sector, speaks at national and international healthcare events and is a key opinion leader for point-of-care testing. Tony co-wrote the British Society of Haematology’s point of care testing guideline for general haematology and remains active across healthcare platforms offering advice and guidance. Through his company he provides educational events and recently launched a website www.POCTInnovators.com which was set up to champion point of care, rapid and decentralised diagnostics.
Mr. Martin Korbmacher is the founder and Managing Partner of Event Horizon Capital & Advisory GmbH. Event Horizon is a Corporate Finance Boutique as well as an investment vehicle.
He studied Mathematics, Physics, and Computer Science, and has spent more than 20 years in various Senior Executive positions in global investment banks in Frankfurt, London, and New York. He began in Fixed Income Trading for JP Morgan, and was the Global Head of Fixed Income as well as the Global Head of Equities for Dresdner Kleinwort. He ended his banking career at Credit Suisse, as the Head of its Investment Banking Division for Germany and Austria.
Mr. Korbmacher holds the position of Chairman of the supervisory board of the publicly listed flatexDEGIRO AG, and is also Chairman of the supervisory board of the publicly listed SGT Private Equity GmbH & Co. KGaA.
NHS Consultant Haematologist at Addenbrooke’s Haematology-Oncology Diagnostic Service (HODS), Cambridge University Hospitals, he is focused on the integrated reporting of haematological malignancies. Prior to Cambridge, he was at Bedford NHS Hospital, Bellvitge Hospital, and MLL Münchner Leukämielabor GmbH in Munich. He has an interest in applications of Machine Learning algorithms to immunophenotypic data and diagnosis of acute myeloid leukemias.
Hamid Sadri is the Director of Policy, Health Economics and Outcomes Research at Medtronic ULC. His work is focused on generating economic evidence and supporting strategic initiatives and policies enabling access to advanced medical technologies for eligible patients who stand to benefit from them. His research has been published in peer-reviewed journals and presented at national and international conferences, and has influenced healthcare policies. Before joining Medtronic in 2006, Hamid worked in various leadership roles in the pharmaceutical industry and in healthcare consulting on three
continents for more than 15 years. Hamid has a doctorate in clinical pharmacy and two graduate degrees, in health economics and healthcare management respectively, from the
University of Toronto. Hamid is a registered pharmacist in Ontario and is a member of the
Canadian College of Health Leaders.
MD & PhD in Neurosciences (Cambridge), NHS Consultant Transplant Surgeon, Professor of Transplantation & Research Group Leader at the Department of Surgery at the University of Cambridge, specialising in transplantation and immunogenicity of cancer and regenerative cellular therapies. More than 20 years of experience in industry with large corporations and startups, including biotech companies. He is the director of the Cambridge In Vivo Assessment Platform and the Cambridge Biorepository for Translational Medicine. He has published over 100 papers, of which more than 20 are in Science and Nature family journals.
PhD in Applied Maths (École Polytechnique) and JD (PhD in law from UPEC) with vast experience working as a strategic advisor for organisations like KPMG, Société Générale and Mars as a Strategic Advisor developing Economics of Mutuality and working in the areas of IP and intangible assets including technology for impact investments. He has experience in Data Science for Derivative Trading, Market risk and Credit risk for Investment Banks, and in Marketing Insight. An expert in Business Development for BioTech and FinTech Startups.
Former Worldwide Director Channel Programs at Microsoft responsible for increasing resellers memberships by 125%, slashing costs by 55% and improving customer satisfaction by 80%, and Regional “Enterprise Customer Unit” Manager for Africa, India and the Middle East based out of London, England growing regional revenues from $8 million USD to over $120 million USD. Has raised $54 million USD and signed over $15 million USD in joint venture deals. BSc in Electrical Engineering, University of Maryland and Executive MBA from the University of Washington, Foster School of Business.
Master’s in Product Design Engineering (University of Strathclyde) and MBA (Vlerick Business School, Leuven), with 20 years technical and commercial experience across the regulated medical diagnostic devices and biotech markets. Former senior R&D engineer at Johnson & Johnson and Product Manager at Intelligent Ultrasound, he has developed, managed and released over 30 electromechanical and diagnostic/AI imaging products, including 11 medical devices (Class IIb) for the global consumer market, including the world’s first AI platform for ultrasound scanning, as integrated into GE Healthcare’s Voluson SWIFT ultrasound machine.
PhD in digital microfluidics (University of Southampton) and former R&D Engineer at Nordson Corporation, he has a particular interest in biosensors, medical diagnostics and imaging with experience predominantly in the development of biomedical and healthcare devices, particularly in the realisation of new and innovative products. Worked at the Centre for Hybrid Biodevices (Nano Research Group, ECS), in partnership with Sharp Labs Europe and Public Health England. His former roles have encompassed customer engagement, product development and the exploration of future technologies.
Masters in Molecular and Cellular Biochemistry (Oxford). Medical Device Compliance Quality Assurance Specialist (CE Marking, FDA (510(k)), ISO 13485 Lead Auditor, 6 Sigma Green Belt, Dipl. Leadership and Management. Several years of experience as a Quality Engineer with global high-tech electronic medical device companies. Has also implemented and worked on IATF 1694, ISO 9001, ISO 14001, TS16949 and AS9100 quality standards and VDA 6,3 process audits. NEBOSH General Certificate.
Scott has an extensive background in corporate development, fundraising strategy and tactical planning. Companies he has successfully helped fund are in diverse industries such as BioTech, MedTech, SaaS, natural resources and cannabis. He has a comprehensive institutional financing network that spans North and South America, Europe and Asia. He has delivered investment results for various private or public entities. His track record of delivering value has been consistent in the private and public markets for over 2 decades.
B.Eng in Electrical Engineering (Boston University) in semiconductors, communications and computer systems, and MSc in Management Information System and Decision Sciences. Former Senior Director for Product Management, responsible for developing cloud transformation strategies and reporting directly to Avolin’s CEO. CRM and KM Guru, SaaS strategist with 20+ years of experience in the computer software industry. Has consulted with some of the world’s largest organisations and delivered business solutions across the United States, Canada, Europe and Asia.
NHS accredited Clinical Safety Officer with more than 20 years experience. Expert in clinical & patient safety, quality standards, risk assessment, CE marking and compliance. She has vast experience in medical devices, medical apps, and the medical technology and equipment sector serving large health technology organisations.
Dr Amdekar is a Senior Anaesthetics Registrar at University College Hospital and an NHS Clinical Entrepreneur Fellow.
She is interested in cancer anaesthesia and peri-operative medicine. Dr Amdekar has undertaken speciality training at Cancer centres, including The Royal Marsden Hospital, MacMillan Cancer Centre. She is an advanced trainee at Royal National ENT hospital specialising in complex airway.
She is a board-certified anaesthetist from The Royal College of Anaesthetists. She graduated from Guy’s, King’s and St. Thomas School of Medine with an Intercalated BSc in Physiology, and completed a research elective at Beth Israel Deaconess Centre, Boston (Harvard) . She has worked closely with various NHS innovation teams and is interested in how biotechnology and digital communications can transform healthcare pathways and patient engagement.
Masters in Translation and Interpretation specialising in communication in the legal & medical fields. She has experience in corporate communication at multinational electronics & manufacturing companies such as Jabil (Research in Motion, Cisco), in journalism, localisation, automatic translation, compliance & ISO standards auditing.
BASc focused in Business Administration and Management and MBA. She was the global president of Welcome Clubs International 2019-2021 and has experience working with for-profit and non-profit organisations to link people with a view to promoting greater understanding and the sharing of knowledge across cultural lines.
PhD (Swiss Federal Institute of Technology ETA Zurich) in Molecular biology with emphasis on protein- and carbohydrate biochemistry and MSc (KTH Royal Institute of Technology) in Biotechnology. Expert in precision nutrition (Level 2 Certification, Toronto, Canada). Knowledge and expertise in precision and population-based nutrition across the life cycle.
Luc brings proven industry experience as a sales and management specialist, with expertise in introducing new technology to the healthcare market. He has fourteen years of commercial experience managing many products in many geographies. He also has experience across many areas within the primary and acute sectors of public healthcare, private health, and the military, and is linked in with an extensive network of key opinion leaders. Luc has won multiple national, European, and international awards for his commercial excellence and has worked with medical technology companies such as Stryker, Sight Diagnostics, Natus, and Belmont Instruments.
Peter Romeo holds a Bachelor of Science in Psychology and has over 21 years of experience in field sales, marketing and executive sales management in the medical device and pharmaceutical spaces. Peter is the former Chief Revenue Officer at Sona Nanotech. He worked as Director of Sales Canada for the Surgical business unit for Teleflex Medical Inc. Peter led the sales team, which drove the acquisition of new market share, repositioning Teleflex as a credible player in the Medical Device industry in Canada. Earlier in his career, he worked at Johnson & Johnson Medical Products Canada, Ethicon Endo-Surgery, and Roche Pharmaceuticals. Peter also led the Canadian Energy franchise to the highest growth rate globally, and has won multiple Sales and Marketing awards, most notably, the distinguished “Global Leadership Award”.
Ramathan Shivaswamy holds a Bachelor’s degree in Electronics and has more than three decades of experience in Sales and Marketing for diagnostic and pharmaceutical product companies.
Ramathan began his career as a Medical Representative in the pharmaceutical industry. He later worked at Becton Dickinson as Regional Manager, covering the southern and western regions, including the SAARC countries. His most recent position was as Divisional Business Head for M/s TransAsia Biomedicals, South division, based in Chennai.
His passion is building customer-oriented teams that pursue excellence in a high-performing culture.
Wendy has over 25 years of experience, profitably managed businesses with full P&L responsibilities, ranging from $2-250MM. She has devised strategic plans at Fortune 500 companies and has led negotiations and cross-functional teams in product portfolio management, marketing and business development. Healthcare leadership roles include: Founder and former Director of Carepoint Medical & Wellness Clinics, Business Director at Johnson & Johnson, Ortho-McNeil, Janssen-Ortho, Glaxo-Smithkline(GSK), Aurora Cannabis, Nexgen Hearing. Director of the Board, BC Cancer Foundation. At Johnson & Johnson Canada, she was the former Director and business lead for OTC Diagnostic Test Kits, Contraceptives & Prophylactics. During her time at Moxie Strategy Inc., a boutique strategy, business development, mergers and acquisition firm she had worked on key development projects in Australia, Canada, United States, Eritrea, Cambodia, Colombia and Africa. She has a Medical Science undergraduate degree from University of British Columbia – with a directed studies on SSRI’s, an MBA in Finance and Marketing from McGill University and ICD.D, Rotman School of Management, University of Toronto. She is fluent in a few Asian languages and conversant in East-West cultures and has successfully led many cross-cultural business development projects.
More than 25 years of experience in sales and marketing management consulting and pharmaceutical line management, specialised in global go-to-market strategies that build sustainable competitive advantage and create marketing and sales organisations. She assists clients in addressing reimbursement and access issues, developing reimbursement strategies, and building capabilities in strategic customer management. Judy has designed and facilitated numerous Advisory Boards throughout the globe (North America, EU, Asia Pacific, and Latin America) on issues ranging from optimising patient care, education, and awareness; current trends and issues in the management of a disease or medical condition; country-specific and/or region-wide guidelines; effective guidelines implementation and knowledge transfer.“
Tracy has a background in HR Management from recruitment and selection of employees, employee engagement, learning and development, compensation, rewards and benefits, and organisational development and uses this to help the company and its people develop and grow.
She will act as a trusted advisor to the management team on all employee and employment-related matters and is the first point of contact for all HR queries.
Tracy has a great interest in people and believes that people are a company’s greatest asset. She has lots of compassion and empathy and will always do “what’s best for the business”.
With her excellent organisational skills and disciplined work approach, Tracy can ensure people come to work feeling fulfilled and enriched, and that’s the job of an HR manager.
